Immunoglobulin: production, mechanisms of action and formulations

Detalhes bibliográficos
Autor(a) principal: Novaretti,Marcia Cristina Zago
Data de Publicação: 2011
Outros Autores: Dinardo,Carla Luana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000500015
Resumo: Human immunoglobulin (Ig) began to be applied in the clinical practice with the treatment of primary immunodeficiencies. Quickly, applications of Ig increased, as its anti-inflammatory and immunomodulatory functions were elucidated. Currently, Ig is the most commonly used blood product. Ig is obtained by processing plasma; methods, in particular, techniques to reduce plasma viral loads have been evolving over the years and include: pasteurization, solvent/ detergent treatment, caprylic acid treatment and nanofiltration. These methods contribute to increased safety and quality of blood products. The mechanisms of action of Ig not only involve the blockade of Fc receptors of phagocytes, but also control complement pathways, idiotype-anti-idiotype dimer formation, blockage of superantigen binding to T cells, inhibition of dendritic cells and stimulation of regulatory T cells (Tregs). There are several formulations of Ig available, each one with its own peculiar characteristics. In Brazil, there is stringent legislation regulating the quality of Ig. Only Ig products that completely fulfill the quality control criteria are released for use. These standards involve different tests from visual inspection to determination of anti-complementary activity. This paper will further review the history and current status of Ig, including its production and mechanisms of action. The formulations available in Brazil and also the criteria of quality control currently applied will be presented.
id ABHHTC-1_739f6ff6db7b4ba49a71998a86443a55
oai_identifier_str oai:scielo:S1516-84842011000500015
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Immunoglobulin: production, mechanisms of action and formulationsImmunoglobulins, intravenous/therapeutic useImmunoglobulins, intravenous/pharmacokineticsPlasmaHemoderivate drugsImmunoglobulinsAntibodiesImmune systemHuman immunoglobulin (Ig) began to be applied in the clinical practice with the treatment of primary immunodeficiencies. Quickly, applications of Ig increased, as its anti-inflammatory and immunomodulatory functions were elucidated. Currently, Ig is the most commonly used blood product. Ig is obtained by processing plasma; methods, in particular, techniques to reduce plasma viral loads have been evolving over the years and include: pasteurization, solvent/ detergent treatment, caprylic acid treatment and nanofiltration. These methods contribute to increased safety and quality of blood products. The mechanisms of action of Ig not only involve the blockade of Fc receptors of phagocytes, but also control complement pathways, idiotype-anti-idiotype dimer formation, blockage of superantigen binding to T cells, inhibition of dendritic cells and stimulation of regulatory T cells (Tregs). There are several formulations of Ig available, each one with its own peculiar characteristics. In Brazil, there is stringent legislation regulating the quality of Ig. Only Ig products that completely fulfill the quality control criteria are released for use. These standards involve different tests from visual inspection to determination of anti-complementary activity. This paper will further review the history and current status of Ig, including its production and mechanisms of action. The formulations available in Brazil and also the criteria of quality control currently applied will be presented.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2011-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000500015Revista Brasileira de Hematologia e Hemoterapia v.33 n.5 2011reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20110102info:eu-repo/semantics/openAccessNovaretti,Marcia Cristina ZagoDinardo,Carla Luanaeng2011-11-23T00:00:00Zoai:scielo:S1516-84842011000500015Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2011-11-23T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Immunoglobulin: production, mechanisms of action and formulations
title Immunoglobulin: production, mechanisms of action and formulations
spellingShingle Immunoglobulin: production, mechanisms of action and formulations
Novaretti,Marcia Cristina Zago
Immunoglobulins, intravenous/therapeutic use
Immunoglobulins, intravenous/pharmacokinetics
Plasma
Hemoderivate drugs
Immunoglobulins
Antibodies
Immune system
title_short Immunoglobulin: production, mechanisms of action and formulations
title_full Immunoglobulin: production, mechanisms of action and formulations
title_fullStr Immunoglobulin: production, mechanisms of action and formulations
title_full_unstemmed Immunoglobulin: production, mechanisms of action and formulations
title_sort Immunoglobulin: production, mechanisms of action and formulations
author Novaretti,Marcia Cristina Zago
author_facet Novaretti,Marcia Cristina Zago
Dinardo,Carla Luana
author_role author
author2 Dinardo,Carla Luana
author2_role author
dc.contributor.author.fl_str_mv Novaretti,Marcia Cristina Zago
Dinardo,Carla Luana
dc.subject.por.fl_str_mv Immunoglobulins, intravenous/therapeutic use
Immunoglobulins, intravenous/pharmacokinetics
Plasma
Hemoderivate drugs
Immunoglobulins
Antibodies
Immune system
topic Immunoglobulins, intravenous/therapeutic use
Immunoglobulins, intravenous/pharmacokinetics
Plasma
Hemoderivate drugs
Immunoglobulins
Antibodies
Immune system
description Human immunoglobulin (Ig) began to be applied in the clinical practice with the treatment of primary immunodeficiencies. Quickly, applications of Ig increased, as its anti-inflammatory and immunomodulatory functions were elucidated. Currently, Ig is the most commonly used blood product. Ig is obtained by processing plasma; methods, in particular, techniques to reduce plasma viral loads have been evolving over the years and include: pasteurization, solvent/ detergent treatment, caprylic acid treatment and nanofiltration. These methods contribute to increased safety and quality of blood products. The mechanisms of action of Ig not only involve the blockade of Fc receptors of phagocytes, but also control complement pathways, idiotype-anti-idiotype dimer formation, blockage of superantigen binding to T cells, inhibition of dendritic cells and stimulation of regulatory T cells (Tregs). There are several formulations of Ig available, each one with its own peculiar characteristics. In Brazil, there is stringent legislation regulating the quality of Ig. Only Ig products that completely fulfill the quality control criteria are released for use. These standards involve different tests from visual inspection to determination of anti-complementary activity. This paper will further review the history and current status of Ig, including its production and mechanisms of action. The formulations available in Brazil and also the criteria of quality control currently applied will be presented.
publishDate 2011
dc.date.none.fl_str_mv 2011-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000500015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000500015
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5581/1516-8484.20110102
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.33 n.5 2011
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213111514005504